Gelteq (NASDAQ:GELS – Get Free Report) and Legend Biotech (NASDAQ:LEGN – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.
Insider and Institutional Ownership
70.9% of Legend Biotech shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings for Gelteq and Legend Biotech, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gelteq | 0 | 0 | 0 | 0 | 0.00 |
| Legend Biotech | 0 | 1 | 8 | 1 | 3.00 |
Valuation and Earnings
This table compares Gelteq and Legend Biotech”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gelteq | N/A | N/A | -$2.33 million | N/A | N/A |
| Legend Biotech | $627.24 million | 10.42 | -$177.03 million | ($0.88) | -40.41 |
Gelteq has higher earnings, but lower revenue than Legend Biotech.
Profitability
This table compares Gelteq and Legend Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gelteq | N/A | N/A | N/A |
| Legend Biotech | -40.83% | -32.00% | -20.07% |
Summary
Legend Biotech beats Gelteq on 7 of the 11 factors compared between the two stocks.
About Gelteq
Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.
About Legend Biotech
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Receive News & Ratings for Gelteq Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gelteq and related companies with MarketBeat.com's FREE daily email newsletter.
